Table 2. Correlations of clinical parameters and T cell markers.
CD4 | CD8 | |||||
Spearman R | p-value | Spearman R | p-value | |||
HCV-RNA | ||||||
HLA-DR+CD38+ | 0.28 | 0.08 | 0.37 | 0.03 | ||
PD1+ | 0.52 | <0.01 | 0.55 | 0.03 | ||
Tim3+ | 0.01 | n.s. | 0.17 | n.s. | ||
Fas+ | 0.20 | n.s. | 0.32 | 0.05 | ||
ALT | ||||||
HLA-DR+CD38+ | -0.09 | n.s. | 0.13 | n.s. | ||
PD1+ | 0.16 | n.s. | 0.26 | n.s. | ||
Tim3+ | -0.17 | n.s. | 0.24 | n.s. | ||
Fas+ | 0.24 | n.s. | 0.12 | n.s. | ||
Liver fibrosis | F0–F2 | F3–F4 | P-value | F0–F2 | F3–F4 | p-value |
HLA-DR+CD38+ | 1.6% | 1.9% | n.s. | 4.4% | 5.4% | n.s. |
PD1+ | 10.2% | 10.4% | n.s. | 14.6% | 9.8% | n.s. |
Tim3+ | 0.6% | 1.1% | n.s. | 0.8% | 0.7% | n.s. |
Fas+ | 57% | 66% | n.s. | 34% | 32% | n.s. |
Spearman correlations of HCV-RNA and ALT with expression of activation and exhaustion markers and median expression of these markers in patients with F0–F2 versus F3–F4 fibrosis in all HCV-monoinfected and HIV/HCV-coinfected patients.